France is 17th country to clear CelSci for patient enrollment in its global phase III head and neck cancer trial
Silence Therapeutics encouraged by kidney disease trial results
Regeneron and Sanofi are purchasing a special voucher held by BioMarin for $67.5 million to hasten FDA review of their drug alirocumab
Visit our sites for b2b sales and banking employees:
Submit an article to cafepharma's CP Wire. Click here to find out more.
| Company | Average | Last 24h |
Increase |
|---|---|---|---|
| Tekmira Pharmaceuticals | 1 | 6 | 500 % |
| Valeant Pharmaceuticals | 3 | 16 | 433 % |
| Allergan | 3 | 15 | 400 % |
| Akamai | 6 | 29 | 383 % |
| Specials Laboratory | 2 | 8 | 300 % |
| Catalent | 1 | 4 | 300 % |
| Charles River Laboratories | 1 | 4 | 300 % |
| Cadila | 2 | 8 | 300 % |
| Sanofi | 9 | 28 | 211 % |
| DaVita | 1 | 3 | 200 % |
| Company | Average | Last 24 hrs |
Increase |
|---|---|---|---|
| Spectrum Pharmaceuticals | 8 | 100 | 1150 % |
| Pacira | 7 | 54 | 671 % |
| Alphatec Holdings | 2 | 15 | 650 % |
| Affymetrix | 7 | 50 | 614 % |
| Biocryst | 14 | 100 | 614 % |
| Solasia | 6 | 38 | 533 % |
| WaferGen Bio-systems | 2 | 12 | 500 % |
| Cell Genesys | 1 | 6 | 500 % |
| NovaBay Pharmaceuticals | 4 | 24 | 500 % |
| Columbia Laboratories | 7 | 41 | 486 % |